


CMO/CDMO Service

CMO/CDMO Partnership

- + Synthesis & Fermentation of API
- + Process Modification, Scale-up, Development, Validation
- + Analytical Method Development & Validation
- + Stability Study follows ICH Guideline
- + CMC Documentation Preparation
- + Services cover from Pre-Clinical to Commercialized stage.

Service Coverage



Always a Team Player

With 75% of our business from North America and Europe, CCSB has been developing and producing APIs and advanced intermediates with leading Brand and Generic drug companies for years.

Established in 1964, CCSB has commercialized several APIs of Anticancer, Antihypertriglyceridemic and Immunosuppressant with complete DMFs.

Our state-of-the-art resources combined with highly skilled contract manufacturing team, we are GMP compliant, responsive, attentive, flexible and trustworthy. CCSB is an outstanding choice of partner to offer all of its clients the highest value.

CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD.

📍 1 Tung-Hsing St., Shu-Lin Dist. 23850, New Taipei City, Taiwan
T +886-2-8684-3318
F +886-2-8684-3202
E ccsb@ccsb.com.tw
🌐 <http://www.ccsb.com.tw>

PHARMAPORTS LLC

📍 1 East Uwchlan Avenue, Suite 116, Exton, PA 19341, USA
T (610) 524-7888
E ppl@pharmaports.com
Toll Free: 1-800-203-1340

CENRA+
API Solutions

Synthetic /
Natural API

Biotech /
Fermentation API

Peptide API



CENRA+ API Solutions

Official cGMP Inspections						
Year	Authorities	Nation	Product			
2024	Münster	Germany	Tacrolimus			
2024	FDA	US	GMP Systems			
2022	FDA	US	MMF			
2021	FDA	US	GMP Systems			
2019	ANSM	France	Methocarbamol			
2018	FDA	US	GMP Systems			
2017	PMDA	Japan	Rapamycin			
2017	FDA	US	Ethyl Icosapentate			
2015	Cofepris	Mexico	Caspofungin Acetate			
2015	Köln	Germany	Pravastatin Sodium; Tacrolimus			
2014	FDA	US	GMP Systems			
2013	MFDS	Korea	Tacrolimus			
2013	PMDA	Japan	Tacrolimus			
2012	Köln	Germany	Pravastatin Sodium			
2011	FDA	US	Dexb; MMF; Tacrolimus			
2009	Köln	Germany	Pravastatin Sodium			
2007	MFDS	Korea	Methocarbamol			
2005	FDA	US	Pravastatin Sodium			

Synthetic / Natural API							
Product Name	DMF	Spec.	Category				
Abaloparatide		In-House	Osteoporosis				
Baricitinib	36030	In-House	Rheumatoid Arthritis				
Brivaracetam		EP	Epilepsy				
Difelikefalin Acetate	38511	In-House	CKD-Associated Pruritus				
Edoxaban Tosylate		In-House	Anticoagulant				
Eltrombopag Olamine		In-House	Hematology				
Eslicarbazepine Acetate	39312	In-House	Epilepsy, Seizures				
Etelcalcetide HCl		In-House	Secondary Hyperparathyroidism with CKD				
Ethyl Icosapentate (EPA>98%)	26271	In-House	Antihypertriglyceridemic; Cardiovascular Risk Reduction				
Lanreotide Acetate		In-House	Acromegaly; Neuroendocrine Tumors				
Ozanimod HCl	37597	In-House	Relapsing Multiple Sclerosis ; Ulcerative Colitis				
Palbociclib	37586	In-House	Breast Cancer				
Plecanatide		In-House	Chronic Idiopathic Constipation				
Ribociclib Succinate	36174	In-House	Breast Cancer				
Ruxolitinib phosphate		In-House	Myelofibrosis, Polycythemia Vera, Graft-versus-host disease, Atopic Dermatitis, Vitiligo				
Selumetinib		In-House	Neurofibromatosis Type 1				
Setmelanotide Acetate		In-House	Genetic Obesity				
Sugammadex Sodium		In-House	Reversal Neuromuscular Blockade				
Tofacitinib Citrate	37532	In-House	Rheumatoid Arthritis; Psoriatic Arthritis				
Trandolapril	17573	EP/USP	Cardiovascular				
Trilaciclib 2HCl		In-House	Myeloprotection				

Biotech / Fermentation API				
Product Name	DMF	Spec.	Category	
Caspofungin Acetate	27585	In-House	Antifungal	
Dalbavancin HCl		In-House	Skin and Skin Structure Infection	
Everolimus	26819 27216 38111	EP/USP	Anticancer; Immunosuppressant	
Midostaurin	36640	In-House	Acute Myeloid Leukemia; Systemic Mastocytosis	
Mycophenolate Mofetil	18494 33333	EP/USP	Immunosuppressant	
Mycophenolate Mofetil HCl	24372	In-House	Immunosuppressant	
Mycophenolate Sodium	35848	EP/USP	Immunosuppressant	
Rapamycin (Sirolimus)	17399 31189	In-House	Immunosuppressant	
Semaglutide		In-House	Diabetes Type 2 (Cardiovascular Risk Reduction); Weight Loss	
Tacrolimus	18985 38310	EP/USP/JP	Immunosuppressant	
Intermediates				
Pneumocandin B0				
Paragraph IV Challenges		Paragraph III		
<ul style="list-style-type: none">• Difelikefalin Acetate• Ozanimod HCl• Setmelanotide Acetate• Trilaciclib 2HCl		<ul style="list-style-type: none">• Eltrombopag Olamine• Eslicarbazepine Acetate• Ribociclib Succinate• Tofacitinib Citrate		
The new pipeline product with unexpired patents on the product list is for the customer’s study and trial purpose only and not for the preparation of commercial launch, if there exists any similar patent. CCSB will not be responsible for any use of the product which may infringe any valid patent.				